Nature Communications (Dec 2016)
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
- Beth O. Van Emburgh,
- Sabrina Arena,
- Giulia Siravegna,
- Luca Lazzari,
- Giovanni Crisafulli,
- Giorgio Corti,
- Benedetta Mussolin,
- Federica Baldi,
- Michela Buscarino,
- Alice Bartolini,
- Emanuele Valtorta,
- Joana Vidal,
- Beatriz Bellosillo,
- Giovanni Germano,
- Filippo Pietrantonio,
- Agostino Ponzetti,
- Joan Albanell,
- Salvatore Siena,
- Andrea Sartore-Bianchi,
- Federica Di Nicolantonio,
- Clara Montagut,
- Alberto Bardelli
Affiliations
- Beth O. Van Emburgh
- Candiolo Cancer Institute—FPO, IRCCS
- Sabrina Arena
- Candiolo Cancer Institute—FPO, IRCCS
- Giulia Siravegna
- Candiolo Cancer Institute—FPO, IRCCS
- Luca Lazzari
- Candiolo Cancer Institute—FPO, IRCCS
- Giovanni Crisafulli
- Candiolo Cancer Institute—FPO, IRCCS
- Giorgio Corti
- Candiolo Cancer Institute—FPO, IRCCS
- Benedetta Mussolin
- Candiolo Cancer Institute—FPO, IRCCS
- Federica Baldi
- Candiolo Cancer Institute—FPO, IRCCS
- Michela Buscarino
- Candiolo Cancer Institute—FPO, IRCCS
- Alice Bartolini
- Candiolo Cancer Institute—FPO, IRCCS
- Emanuele Valtorta
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda
- Joana Vidal
- Medical Oncology Department, Hospital del Mar
- Beatriz Bellosillo
- Cancer Research Program, FIMIM (Hospital del Mar Medical Research Institute), Hospital del Mar
- Giovanni Germano
- Candiolo Cancer Institute—FPO, IRCCS
- Filippo Pietrantonio
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori
- Agostino Ponzetti
- Medical Oncology Division 1, Colorectal Cancer Unit, San Giovanni Battista Hospital
- Joan Albanell
- Medical Oncology Department, Hospital del Mar
- Salvatore Siena
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda
- Andrea Sartore-Bianchi
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda
- Federica Di Nicolantonio
- Candiolo Cancer Institute—FPO, IRCCS
- Clara Montagut
- Medical Oncology Department, Hospital del Mar
- Alberto Bardelli
- Candiolo Cancer Institute—FPO, IRCCS
- DOI
- https://doi.org/10.1038/ncomms13665
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 9
Abstract
Some colorectal cancer patients respond well to treatment with anti-EGFR antibodies, however response is almost invariably followed by acquired resistance. Here, the authors show that patients with shorter responses acquireRAS mutations, while those relapsing later preferentially develop mutations in the extracellular domain of EGFR.
